Suchergebnisse - "Almotlak, Abdulaziz A"

PubPharm (6)

1

Cancer Research Challenges and Potential Solutions in Saudi Arabia : A Qualitative Discussion Group Study

enthalten in: JCO global oncology | 2024

von Alessy, S. | Almotlak, A. | Alattas, M. | +5

2

Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T cell Mediated Anti-Tumor Response and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression

enthalten in: bioRxiv.org | 2022

von Kilic, O. | de Souza, M. | Almotlak, A. | +2

3

Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy

enthalten in: International journal of molecular sciences | 2021

von Almotlak, A. | Farooqui, M. | Soloff, A. | +2

4

Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression

enthalten in: Journal of medicinal chemistry | 2020

von Kilic, O. | Matos de Souza, M. | Almotlak, A. | +4

5

Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor

enthalten in: Cancer prevention research (Philadelphia, Pa.) | 2020

von Njatcha, C. | Farooqui, M. | Almotlak, A. | +1

6

Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Almotlak, A. | Farooqui, M. | Siegfried, J.

CommentIn: Transl Lung Cancer Res. 2020 Aug;9(4):1599-1605. - PMID 32953532

1
[1]